SOLICITATION NOTICE
Q -- Procurement of Serum Samples from Subjects to Assess Circulating Markers That May Be Associated With Lobular Involution
- Notice Date
- 7/14/2015
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52597-76
- Archive Date
- 7/29/2015
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP), plans to procure on a sole source basis serum samples from subjects from the Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center, University Hospital, 550 University Blvd., Room 6042, Indianapolis, IN 46202. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract. The period of performance of the Firm-Fixed Price contract shall be for twelve (12) months from the date of the award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. The Epidemiology and Biostatistics Program (EBP) conducts independent and collaborative epidemiologic and biostatistical investigations to identify the distribution, characteristics, and causes of cancer in human populations. These aims are accomplished through a series of integrated programs of research. Blood levels of growth factors have been previously found to be positively related to breast cancer risk and mammographic density, primarily among premenopausal women; and analysis in the Breast Radiology Evaluation and Study of Tissues (BREAST) Stamp Project from the NCI Hormonal and Reproductive Epidemiology Branch (HREB) has shown an association with IGF-1 and IGFBP-3 and higher TDLU counts suggesting, that this may be an important pathway that inhibits TDLU involution. The NCI investigators want to replicate this work and enhance their understanding of how IGF's may influence TDLU involution, using the KTB study samples, a unique source of normal breast tissues, risk factor data, and blood from volunteers for research. Greater degrees of terminal duct lobular unit (TDLU) involution have been linked to lower breast cancer risk; however, factors that influence this process are poorly characterized. The National Cancer Institute (NCI) has been approved to test serum samples in the Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center (KTB), and will specifically select 1,012 samples among 1,938 women subjects whose hematoxylin and eosin stained sections (H&E's) have been reviewed. The NCI has performed morphometric assessment of TDLUs and developed three (3) reproducible quantitative measures that are inversely associated with TDLU involution: TDLU counts per standardized biopsy, median acini counts/TDLU and median TDLU span in order to identify factors associated with TDLU involution in normal breast tissues from the KTB. The women were participants in the KTB repository, and have given consent to participate in research. These samples are needed in order to support the comprehensive, multidisciplinary, intramural research program within the DCEG. Contractor shall provide: • (1,012) 600ul aliquots of serum collected from participants in the KTB study in order to assess circulating markers and their association with TDLU involution. • the samples shall be shipped frozen on dry ice, and the Contractor shall provide a specimen manifest in the shipment. • the NCI COR any issues with the samples and will inform the NCI COR if samples from subjects are not available in order to determine if replacement subjects are needed. The NCI will provide to the Contractor a list of subjects who have been assessed for TDLU involution measures and for whom serum samples are desired and the address and contacts where the samples should be sent. This required service is provided by the Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center. The scope of this requirement can only be completed by the proposed source, the KTB, the only known repository of normal breast tissues with epidemiologic data and biologic samples. The study is ongoing, and the performance characteristics and quality of the needed services are required for maintaining the integrity of the on-going study. A change would be disruptive to the ability to analyze the study's cumulative results. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 8:00AM EDT, on July 28, 2015. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02CP52597-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52597-76/listing.html)
- Record
- SN03796998-W 20150716/150715000216-ee59fc52fdb16e827a0e06b0f326284a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |